Total Payments
$1.3M
2024 Payments
$114,820
Companies
29
Transactions
771
Medicare Patients
1,350
Medicare Billing
$205,793
Payment Breakdown by Category
Consulting$716,320 (54.4%)
Other$420,126 (31.9%)
Research$106,280 (8.1%)
Travel$62,172 (4.7%)
Food & Beverage$10,854 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $716,320 | 207 | 54.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $383,626 | 133 | 29.2% |
| Unspecified | $106,280 | 61 | 8.1% |
| Travel and Lodging | $62,172 | 176 | 4.7% |
| Honoraria | $36,500 | 14 | 2.8% |
| Food and Beverage | $10,854 | 180 | 0.8% |
Payments by Type
General
$1.2M
710 transactions
Research
$106,280
61 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $345,930 | 218 | $0 (2024) |
| PFIZER INC. | $295,834 | 184 | $0 (2024) |
| GENZYME CORPORATION | $161,502 | 85 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $113,904 | 29 | $0 (2024) |
| Exelixis Inc. | $87,495 | 57 | $0 (2023) |
| Merck Sharp & Dohme LLC | $81,808 | 50 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $64,966 | 29 | $0 (2024) |
| AstraZeneca UK Limited | $30,230 | 27 | $0 (2024) |
| Astellas Pharma US Inc | $23,651 | 11 | $0 (2024) |
| Janssen Research & Development, LLC | $15,070 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $114,820 | 91 | Bayer Healthcare Pharmaceuticals Inc. ($37,131) |
| 2023 | $210,774 | 78 | AstraZeneca Pharmaceuticals LP ($86,538) |
| 2022 | $157,125 | 89 | Bayer HealthCare Pharmaceuticals Inc. ($39,335) |
| 2021 | $130,161 | 59 | PFIZER INC. ($34,094) |
| 2020 | $153,794 | 79 | Bayer HealthCare Pharmaceuticals Inc. ($53,970) |
| 2019 | $154,735 | 94 | Bayer HealthCare Pharmaceuticals Inc. ($69,603) |
| 2018 | $216,220 | 173 | Bayer HealthCare Pharmaceuticals Inc. ($82,426) |
| 2017 | $178,122 | 108 | PFIZER INC. ($64,716) |
All Payment Transactions
771 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $5,573.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 12/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 12/16/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,700.00 | General |
| 12/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 12/13/2024 | PFIZER INC. | TALZENNA (Drug) | Travel and Lodging | Cash or cash equivalent | $178.50 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/05/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $320.56 | General |
| 12/05/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $188.05 | General |
| 12/04/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $568.60 | General |
| 12/04/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $157.30 | General |
| 11/22/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $6,150.00 | General |
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 10/15/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | — | Cash or cash equivalent | $2,260.18 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 10/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 10/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 10/10/2024 | Novartis Pharma AG | PLUVICTO (Drug), LOCAMETZ | — | In-kind items and services | $237.67 | Research |
| Study: CAAA617B12302 • Category: ONCOLOGY | ||||||
| 09/19/2024 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $2,920.00 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $147.14 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $38,050 | 27 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $21,557 | 1 |
| SUNITINIB MALATE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,880 | 6 |
| RELUGOLIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $5,820 | 1 |
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $4,121 | 1 |
| DECIDER | Astellas Pharma Global Development | $3,729 | 9 |
| PUBLICATION DEVELOPMENT SUPPORT IN RELATION TO THE HISTORICAL OVERVIEW OF METASTATIC PROSTATE CANCER THERAPY AND GONADTROPIN-RELEASING HORMONE ANTAGONISTS INCLUDING RELUGOLIX | Myovant Sciences Inc. | $3,075 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $2,260 | 1 |
| SUNITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| AB -1179532023 - Patient Characteristics, Treatment Patterns and Outcomes among Early Adopters of Lutetium Lu 177 Vipivotide Tetraxetan (177 Lu-PSMA-617): A Real-World United States (US) Study. | Novartis Pharmaceuticals Corporation | $1,188 | 1 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $812.00 | 1 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $810.00 | 1 |
| A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naive Prostate Cancer | Astellas Pharma Global Development | $486.00 | 1 |
| PF06821497 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| HEOR | Novartis Pharmaceuticals Corporation | $254.64 | 1 |
| CAAA617B12302 | Novartis Pharma AG | $237.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 262 | 443 | $150,592 | $42,348 |
| 2022 | 5 | 370 | 606 | $201,613 | $57,705 |
| 2021 | 5 | 368 | 637 | $206,653 | $60,565 |
| 2020 | 5 | 350 | 607 | $192,867 | $45,176 |
Total Patients
1,350
Total Services
2,293
Medicare Billing
$205,793
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 171 | 333 | $114,552 | $32,770 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 76 | $19,380 | $5,234 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 34 | 34 | $16,660 | $4,344 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 215 | 424 | $145,856 | $42,652 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 52 | 52 | $25,526 | $6,962 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 76 | 100 | $25,500 | $6,508 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 19 | $3,268 | $824.09 | 25.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 11 | 11 | $1,463 | $757.85 | 51.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 191 | 425 | $146,200 | $43,802 | 30.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 104 | 132 | $33,660 | $8,622 | 25.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 45 | 45 | $22,050 | $6,241 | 28.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 17 | 23 | $2,679 | $1,366 | 51.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 12 | $2,064 | $532.48 | 25.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 172 | 397 | $136,568 | $30,701 | 22.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 81 | 103 | $26,265 | $5,625 | 21.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 45 | 45 | $22,096 | $5,483 | 24.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 39 | 47 | $5,358 | $2,790 | 52.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 13 | 15 | $2,580 | $577.12 | 22.4% |
About Dr. Daniel George, M.D
Dr. Daniel George, M.D is a Urology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124101381.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel George, M.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $114,820 received in 2024. These payments were reported across 771 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($716,320).
As a Medicare-enrolled provider, George has provided services to 1,350 Medicare beneficiaries, totaling 2,293 services with total Medicare billing of $205,793. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Durham, NC
- Active Since 10/23/2006
- Last Updated 07/08/2007
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1124101381
Products in Payments
- Xofigo (Drug) $172,341
- JEVTANA (Drug) $158,870
- SUTENT (Drug) $122,376
- LYNPARZA (Drug) $97,515
- Nubeqa (Drug) $84,359
- XTANDI (Drug) $70,071
- Cabometyx (Drug) $69,440
- TALZENNA (Drug) $48,825
- Xtandi (Drug) $22,460
- VOTRIENT (Drug) $21,615
- CABOMETYX (Drug) $18,055
- ORGOVYX (Drug) $16,909
- PLUVICTO (Drug) $16,474
- INLYTA (Drug) $10,889
- Erleada (Drug) $10,836
- Lenvima (Drug) $10,695
- Bavencio (Biological) $8,540
- LUTATHERA (Drug) $7,200
- Non-Covered (Drug) $6,929
- YERVOY (Biological) $6,300
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Durham
Judd Moul, M.d, M.D
Urology — Payments: $1.2M
Urology $1.2M
Glenn Preminger, M.d, M.D
Urology — Payments: $866,632
Urology $866,632
Brant Inman, M.d, M.D
Urology — Payments: $472,029
Urology $472,029
Dr. Michael Lipkin, Md, MD
Urology — Payments: $304,475
Urology $304,475
Mr. Jay Kim, Md, MD
Urology — Payments: $245,916
Urology $245,916
Dr. Andrew Peterson, Md, MD
Urology — Payments: $204,892
Urology $204,892